Theromo Fisher Scientific£¨ÈüĬ·ÉÊÀ¶û¿Æ¼¼¹«Ë¾£©ÊÇ2016ÄêÈ«ÇòÁìÏȵĿÆÑ§ÒÇÆ÷Éú²úÉÌ£¬ÆìÏÂÓµÓÐÒ»´ú²âÐòºÍÓ«¹â¶¨Á¿pCR¼¼ÊõµÄÒµÄÚ¶¥¼¶Æ·ÅÆapplied biosystems¡¢¶þ´ú²âÐò¼¼ÊõµÄÒµÄÚ¶¥¼¶Æ·ÅÆIon Torrent¡¢»ùÒòоƬ¼¼ÊõµÄÒµÄÚ¶¥¼¶Æ·ÅÆAffymetrixµÈ¡£

ÎÒÃÇÄܹ»Ìṩ¶ùͯ¼²²¡·Ö×Ó¼ì²â´ÓÑùÆ·µ½½á¹ûµÄÍêÕû²úÆ·½â¾ö·½°¸¡£

Ò»¡¢¸ßͨÁ¿²âÐò¼¼Êõ£¨¶þ´ú²âÐò£©ÔÚ¶ùͯ¼²²¡Ïà¹Ø·Ö×Ó¼ì²âÖеÄÑо¿ºÍÁÙ´²Ó¦ÓÃ

1¡¢¼¼Êõ¶¨Î»

¸ßͨÁ¿²âÐòÊʺÏÓÃÓÚ¶à»ùÒò»ò¶àλµãÏà¹ØµÄ¼²²¡µÄ·Ö×ÓÕï¶Ï£¬°üÀ¨ÒÑÖª±äÒì/²¡ÒòµÄ¼ì²âºÍδ֪±äÒì/²¡ÒòµÄɸ²é¡£È縴µ©´óѧ¸½Êô¶ùͯҽԺ»ùÓÚ¸ßͨÁ¿²âÐò¼¼ÊõÒÑ¿ªÕ¹ÁËÐÂÉú³£¼û»ûÐÎɸ²é¡¢ÌÇÔ­ÀÛ»ý²¡¡¢ÐÔÏÙ·¢Óý²»È«¡¢ÉúÖ³Õϰ­¡¢¶ùͯº±¼û²¡¡¢±½±ûͪÄòÖ¢¡¢¶ùͯÖ×ÁöµÈ¡£

2¡¢ÍƼö²úÆ·¡ª¡ªIon S5¸ßͨÁ¿²âÐòϵͳ£¨2015Äê×îвúÆ·£©

3¡¢¿É¿ªÕ¹µÄÁÙ´²ÏîÄ¿»òÑо¿¡ª¡ªÒÅ´«²¡¡¢º±¼û²¡¡¢ÑªÒº²¡¡¢·¢ÓýºÍ´úл¼²²¡µÈ·Ö×Ó¼ì²â

ÎÒÃÇÌṩҵÄÚ×î¶à¡¢ÖÖÀà×îÈ«µÄÒÅ´«²¡·çÏÕ¼ì²â/Ñо¿µÄ¸ßͨÁ¿²âÐòÊÔ¼ÁºÐ½â¾ö·½°¸£¬º­¸Ç´úлϵͳ¡¢Éñ¾­ÏµÍ³¡¢ÃâÒßϵͳ¡¢ÑªÒºÏµÍ³¡¢¶úÁû/ÌýÁ¦Ëðʧ¡¢ÖÇÁ¦/·¢ÓýµÈÏà¹Ø¼²²¡¡£

ͬʱ£¬ÎÒÃÇÒ²Ö§³Ö×ÔÓɶ¨ÖÆ£¨Ion AmpliSeq Designer£©panel£¬Âú×㲻ͬҽԺ¶Ô¸÷ÖÖ¼²²¡·Ö×Ó¼ì²âµÄ¸öÐÔ»¯ÐèÇó¡£

ÀýÈ磺ÏÂÃæÊǿͻ§¶¨ÖƵĺ­¸Ç5ÖÖ³£¼û¶ùͯÒÅ´«²¡µÄpanelÐÅÏ¢¼°Æä¼ì²â½á¹ûºÍ±¨¸æ¡£

ÊÊÓÃÈËȺ£ºÐÂÉú¶ù£¬ÔÐÔçÆÚÌ¥¶ù£¨ÑòË®£©£¬Óв¡Ê·»ò¼Ò×åÊ·£»ÈËȺ×ÛºÏЯ´øÂÊÔ¼´óÓÚ10%£¬ÈËȺ×ۺϻ¼²¡ÂÊ´óÓÚ1%£¬×ۺϼì³öÂÊ´óÓÚ80%¡£

¼²²¡Ãû³Æ

£¨·¢²¡ÂÊ£©

¼ì²â»ùÒò

ÍâÏÔ×Ó¡¢Í»±äλµã

ÐÂÉú¶ù¼ì²âÒâÒå

µØÖк£Æ¶Ñª

(¦ÁÐÍ¡¢¦ÂÐÍ)

£¨1%-16% ²»Í¬µØÇø£©

HBA1¡¢HBA2¡¢HBB

Ö¢×´·¢ÉúǰԤ·À²¢ÖÎÁÆ¿ÉÓÐЧ¼õÉÙ²¢·¢Ö¢£¬Èç·¢Óý²»Á¼£¬ÖÇÁ¦³Ù¶ÛµÈ£¬Í¬Ê±¼ì²â³ö¦Á¦Â¸´ºÏÐÔµØÆ¶¿É±ÜÃâ´íÎóÖÎÁÆ´øÀ´µÄÉ˺¦µÄ

ѪÓѲ¡

(AÐÍ¡¢BÐÍ£©

1/5000 ÐÂÉú¶ù

F8¡¢F9

¾¡Ôç·¢ÏÖ²¢·ÖÐÍ£¬ÒÔ½øÐÐ֢״ǰÖÎÁÆ£¬¼õÉÙÒÖÖÆÎï²úÉú¸ÅÂÊ£¬Ìá¸ßÁÆÐ§¼õÉÙÖ§³ö£¬¿ÉʹÊÙÃü´ïµ½Õý³£ÈËˮƽ£»¶ÔÓÚÖÐÐ;¡Ôç·¢ÏÖ¿ÉÔ¤·À¹Ø½Ú»ûÐΣ¬ÇáÐÍ»¼ÕßÄÑÒÔÈ·Õ¿ÉÄÜÔÚÊÖÊõʱ³öÏÖ´ó³öѪ²ÅÕï¶Ï£¬Õâ»á´øÀ´ºÜ´óµÄÒâÍâΣº¦

±½±ûͪÄòÖ¢

1/10000

pAH

³öÉúÔçÆÚʱ·¢²¡Ç°·¢ÏÖ²¢¼°Ê±ÖÎÁƿɲ»Ôì³ÉÈκÎÉ˺¦£¬·ñÔòÔÚ·¢²¡ºó»á²úÉú²»¿ÉÄæµÄÖÇÁ¦ËðÉË

³ÉÈ˶àÄÒÉö

1/200~1/1000

pKD1¡¢pKD2

ÌáǰԤ·À²¢·¢Ö¢£¬¼õÉÙÍ´¿àºÍÖ§³ö£¬ÑÓ³¤ÊÙÃü£»ÐÂÉú¶ùЯ´øÕߵļì³ö¿ÉÒÔÓÐЧԤ·ÀÆäÔÚÇàÄ겡·¢Ç°Éú³öÖ²¡µÄº¢×Ó£¬¶øÊ¹¼²²¡´ú´úÏà´«

ÒÅ´«ÐÔ¶úÁû

1/1000

COL11A2£¬SLC26A4£¬

GJB2, GJB3£¬GJB6, 12S

±ÜÃâÒ©Îï¹ýÃôÐÔ¶úÁûºÍÕðµ´ÐÔ¶úÁû

ÏÂÃæÎª5ÖÖÒÅ´«²¡panel¼ì²â½á¹ûºÍ±¨¸æ

4¡¢¿Í»§¿ªÕ¹µÄÏîÄ¿¾ÙÀý

£¨1£©¸´µ©´óѧ¸½Êô¶ùͯҽԺ

¿Í»§»ùÓÚÎÒÃǵĸßͨÁ¿²âÐòÔÚÏßpanel¶¨Öƹ¤¾ß£¨£¨Ion AmpliSeq Designer£©£¬¶¨ÖÆÁ˶à¸öÓë¶ùͯÒÅ´«²¡¡¢·¢Óý¡¢´úл¡¢Ö×ÁöÏà¹ØµÄ¼ì²âpanel¡£


£¨×¢£º½ØÍ¼À´×Ô¿Í»§¹«¿ª±¨¸æppT£©

£¨2£©Î人ͬ¼ÃÒ½Ôº


£¨×¢£º½ØÍ¼À´×Ô¿Í»§¹«¿ª±¨¸æppT£©

£¨3£©Ö£ÖÝ´óѧµÚÒ»¸½ÊôÒ½Ôº

¿ªÕ¹µÄÒÅ´«²¡¼ì²âÏîÄ¿°üÀ¨£º±½±ûͪÄòÖ¢¡¢¼×»ù±û¶þËáѪ֢¡¢°×»¯²¡¡¢¶ÅÊÏ\±´Êϼ¡ÓªÑø²»Á¼¡¢ÑªÓѲ¡¡¢¸Î¶¹×´ºË±äÐÔ¡¢Éñ¾­ÏËάÁö¡¢´óðåÐÔ±íÆ¤ËÉи֢¡¢ÄáÂüÆ¥¿ËѪ֢¡¢·¶¿ÉÄáÆ¶Ñª¡¢¶à·¢ÐÔ¹ÇÈí¹ÇÁö¡¢Éñ¾­ÏËάÁö¡¢¶àÄÒÉö¡¢½á½ÚÐÔÓ²»¯¡¢XÁ¬ËøÎÞ±ûÖÖÇòµ°°×Ѫ֢¡¢ÒÅ´«ÐÔÇòÐκìϸ°ûÔö¶àÖ¢¡¢°×ÄÚÕÏ¡¢ÊÓÍøÄ¤É«ËØ±äÐԵȡ£

³ýÁËÒÔÉϵ¥Î»Í⣬ÎÒÃǺܶàÆäËû¿Í»§Ò²ÔÚ¿ªÕ¹»ùÓÚ¸ßͨÁ¿²âÐò¼¼Êõ½øÐжùͯ¼²²¡Ïà¹ØµÄ·Ö×Ó¼ì²â¡£ÀýÈ磺ÉϺ£¶ùͯҽѧÖÐÐÄ¡¢Ð»ªÒ½Ôº¡¢ÉϺ£¶ùͯҽԺ¡¢±±¾©¶ùÑÐËù¡¢½­ËÕÊ¡ÈËÃñÒ½Ôº¡¢ËÕÖݶùͯҽԺ¡¢Î人ÊжùͯҽԺµÈ¡¢±±¾©¶ùͯҽԺ¡£

5¡¢¹úÄÚ¿Í»§·¢±íµÄÎÄÕ¾ÙÀý

1. A functional variant in ApOA5/A4/C3/A1 gene cluster contributes to elevated triglycerides and severity of CAD by interfering with microRNA 3201 binding efficiency

ͨѶ×÷ÕߣºÍôµÀÎÄ£¨Î人ͬ¼ÃÒ½Ôº£©
·¢±íÔÓÖ¾£ºJ Am Coll Cardiol, 2014, 64: 267-277 Ó°ÏìÒò×Ó£º17.759
ÄÚÈݼò½é£ºÀûÓÃÒ»´ú²âÐò¡¢¶þ´ú²âÐòºÍÓ«¹â¶¨Á¿pCR¼¼ÊõÑо¿ApOA5/A4/C3/A1»ùÒò´Ø¶à̬ÐÔÄÜÓ°Ïì¸ÊÓÍÈýËáõ¥£¨TG£©Ë®Æ½¼°¹Ú×´¶¯Âö¼²²¡£¨CAD£©µÄ·Ö×Ó»úÖÆ

2. ÎÄÏײμûÏÂͼ½éÉÜ£¨pLOS ONEÓ°ÏìÒò×Ó3.057£©

3. NGS-based 100-gene panel of hypopigmentation identifies mutations in Chinese Hermansky¨Cpudlak syndrome patients

ͨѶ×÷ÕߣºÀîΡ£¨±±¾©¶ùͯҽԺ£©
·¢±íÔÓÖ¾£ºpigment Cell and Melanoma Research. 2016, 29:702-706Ó°ÏìÒò×Ó£º4.163
ÄÚÈݽéÉÜ£ºHermansky-pudlak×ÛºÏÕ÷(HpS)ÊǾßÓÐÉ«ËØÈ±Ê§±íÏÖ²¢°éÓгöѪÇãÏòµÈ±íÐ͵ÄÒ»ÀàÒÅ´«ÐÔ¼²²¡£¬Óë¶àÖÖÈÜøÌåÏà¹ØÏ¸°ûÆ÷(LRO)µÄȱÏÝÓйØ¡£Ä¿Ç°ÒÑÈ·¶¨µÄHpSÑÇÐÍÓÐ10ÖÖ£¬°üÀ¨HpS1-HpS10»ùÒòÍ»±ä¡£ÔÚÖйúÈËȺÖнö±¨µÀ¹ý4ÀýHpS-1µÄ²¡ÈË¡£ÔÚ±¾Ñо¿ÖУ¬ÎÒÃÇÀûÓöþ´ú²âÐò¼¼Êõ(NGS)£¬¶Ô¾ßÓеäÐÍÑÛÆ¤·ô°×»¯²¡±íÐÍÒÔ¼°ÑªÐ¡°åÖÂÃÜ¿ÅÁ£È±Ê§±íÐ͵ÄÖйúHpS²¡ÈË£¬Ñ¡Ôñ100¸öÓëÉ«ËØ¼õÍËÓйصĻùÒò½øÐÐÁ˼ì²â£¬¼ø¶¨³ö4ÀýHpS-1Í»±ä¡¢2ÀýHpS-3Í»±ä¡¢1ÀýHpS-5Í»±äºÍ3ÀýHpS-6Í»±ä¡£ÔÚÕâЩ²¡ÈËÖУ¬1ÀýΪ´¿ºÏÍ»±ä£¬ÆäÓà¾ùΪ¸´ºÏÔÓºÏÍ»±ä¡£ÔÚÕâЩ»ùÒòÍ»±äÖУ¬ÓÐ14¸öÍ»±äλµãÊÇ֮ǰδ¼û±¨µÀµÄ(ÆäÖУ¬HpS1»ùÒòÓÐ4¸ö¡¢HpS3»ùÒòÓÐ3¸ö¡¢HpS5»ùÒòÓÐ2¸ö¡¢HpS6»ùÒòÓÐ5¸ö)¡£±¾Ñо¿½á¹ûÖ¤Ã÷Á˶þ´ú²âÐòÔÚHpSÕï¶ÏÖÐÊǷdz£ÊµÓúÍÓÐЧµÄ¡£¶ø¶ÔÓÚHpSÑÇÐ͵ĻùÒòÐÍ·ÖÐÍ£¬ÊǶԸ÷ÑÇÐÍÌØÒìÐÔÖ¢×´µÄ¸öÌ廯ÖÎÁƵÄÏȾöÌõ¼þ¡£


¶þ¡¢»ùÒòоƬ¼¼ÊõÔÚ¶ùͯ¼²²¡Ïà¹Ø·Ö×Ó¼ì²âÖеÄÓ¦ÓÃ

1¡¢¼¼Êõ¶¨Î»

»ùÒòоƬÊʺÏÓÃÓÚ¶à»ùÒò»ò¶àλµãÏà¹ØµÄ¼²²¡µÄ·Ö×ÓÕï¶Ï£¬ÌرðÊʺÏȾɫÌåÊýÄ¿»ò½á¹¹Òì³£Ïà¹Ø¼²²¡µÄ¼ì²â¡£ÀýÈ磺ÓëȾɫÌåÒì³£Ïà¹ØµÄÏÈÌìÐÔ¼²²¡£¨Èç¶ùͯ·¢Óý³Ù»º»òÖÇÁ¦Õϰ­µÈ£©£¬·ÇÒÑÖª×ÛºÏÕ÷µÄ¶à·¢»ûÐΣ»×Ô±ÕÖ¢Æ×ϵÕϰ­£¬ÒÔ¼°È¾É«Ìå½á¹ûÒì³££¨È±Ê§ÓëÖØ¸´£©µÄ¼ì²âµÈ¡£

2¡¢ÍƼö²úÆ·¡ª¡ªAffymetrix GeneChip® System (GCS) 3000Dx v.2 (Dx2)»ùÒòоƬϵͳ

GeneChip® System (GCS) 3000Dx v.2ÊÇÁÙ´²Ñо¿×î¿É¿¿µÄ»ùÒòоƬƽ̨£¬Ò²ÊÇΨһһ¿î¾­ÃÀ¹úFDAºÍÖйúCFDAÅú×¼¡¢´øÓÐÅ·ÖÞCE¨CIVDÈÏÖ¤µÄоƬϵͳ£¬ÊʺϻùÓÚRNAºÍDNAµÄÁÙ´²¼ì²â£¬È«ÃæÖ§³Ö»ùÒòоƬµÄ¸÷ÖÖÓ¦Ó㬰üÀ¨»ùÒò±í´ï¡¢»ùÒò·ÖÐÍ¡¢Ï¸°ûÒÅ´«Ñ§¡¢±í¹ÛÒÅ´«Ñ§¡¢¿½±´Êý±äÒì¡¢ÔÙ²âÐòºÍTilingµÈ¡£

¸Ã»ùÒòоƬϵͳ°üÀ¨ÔÓ½»ÒÇ¡¢Ï´µÓ¹¤×÷Õ¾¡¢É¨ÃèÒǺͼÆËã»ú¹¤×÷Õ¾µÈËĸö²¿·Ö£¬¿É×Ô¶¯Íê³ÉAffymetrixËùÓп¨Ê½Ð¾Æ¬µÄÔÓ½»¡¢Ï´µÓ¡¢É¨Ãè¼°³õ²½Êý¾Ý·ÖÎö¡£

3¡¢¿É¿ªÕ¹µÄÁÙ´²ÏîÄ¿»òÑо¿¡ª¡ªÒÅ´«²¡¡¢·¢ÓýÒì³£¡¢ÑªÒº²¡¡¢¶úÁû¼²²¡µÈ·Ö×Ó¼ì²â

»ùÒòоƬ¼¼Êõ¿ÉÔÚÈ«»ùÒò×鷶ΧÄÚ¼ì²âµ½È¾É«ÌåµÄȱʧºÍÔö¼Ó²¢ÄÜ׼ȷµØ²â¶¨Æä´óС£»¿Éͬʱ¼ì²â¶àÖÖÒòȾɫÌåʧºâ¶øµ¼Öµļ²²¡£¨±ÈÈçÔÓºÏÐÔȱʧ£¨LOH£©¡¢µ¥Ç×¶þ±¶Ì壨UpD£©£©£»¿É¼ì²âµ½¡Ý20%ˮƽµÄǶºÏÌ壻²¢ÇÒ·Ö±æÂʸߣ¬¿ÉÒÔÈ·¶¨50kbµÄÖØ¸´£¨gain)¼°25kbµÄȱʧ£¨loss)£¬Ïà±È´«Í³ºËÐÍ·ÖÎö¸ß³ö½üǧ±¶¡£

¶à¸ö¹ú¼ÒµÄÐÐҵЭ»á£¬ÀýÈ磺ÃÀ¹úÒÅ´«Ñ§Ð­»á£¨ACOG£©¡¢¹ú¼Êϸ°ûоƬ±ê׼ίԱ»á£¨ISCA£© µÈ¾ùÍÆ¼ö½«»ùÒòоƬ¼¼ÊõÓÃÓÚ¶ùͯÒÅ´«²¡µÄÕï¶ÏºÍÑо¿¡£2010Ä꣬¼ÓÄôóÒÅ´«Ð­»á£¨CCMG£©ÍƼöоƬ¼¼ÊõÓÃÓÚÒÔϲúºóÖ¸Õ÷£ºÔ­·¢ÐÔÖÇÁ¦µÍÏÂ/Éú³¤ ·¢Óý³Ù»º/×Ô±ÕÖ¢/¶à·¢ÐÔÏÈÌì»ûÐΣ»ÐÂÍ»·¢Ã÷ÏÔµÄȾɫÌ寽ºâÒìλ»òÒÅ´«×Ô±íÐÍÕý³£µÄÇ×´ú£»²»Ôлò·´¸´×ÔÈ»Á÷²ú·ò¸¾¡£¶ù¿ÆÑ§ÔÓÖ¾£¨pediatrics£©2010Äê4Ô¿¯ÍƼöоƬ¼¼Êõ×÷Ϊ¹Â¶ÀÖ¢Ê×Ñ¡Õï¶Ï¼¼Êõ¡£

2016Äê6Ôµġ¶Öлª¶ù¿ÆÔÓÖ¾¡·Ò²·¢±íÁË¡¶È¾É«Ìå»ùÒò×éоƬÔÚ¶ù¿ÆÒÅ´«²¡µÄÁÙ´²Ó¦ÓÃר¼Ò¹²Ê¶¡·£¬Ã÷È·Ö¸³ö£ºÈ¾É«Ìå΢ÕóÁÐ/CMA/»ùÒòоƬ¿É×÷ΪһÏß¼ì²âÊÖ¶ÎÓÃÓÚ£º£¨1£©²»Ã÷Ô­ÒòµÄÖÇÁ¦ÂäºóºÍ£¨»ò£©·¢Óý³Ù»º¡££¨2£©·ÇÒÑÖª×ÛºÏÕ÷µÄ¶à·¢»ûÐΡ££¨2£©×Ô±ÕÖ¢Æ×ϵÕϰ­¡£

Affymetrix CytoScan HDоƬϵͳӵÓÐÒµÄÚ×î¸ßµÄ̽ÕëÃܶÈ¡¢»ùÒò¸²¸Ç¶È£¨¼ûÏÂ±í£©¡¢·Ö±æÂʺÍÐÔÄܱíÏÖ¡£Æäͬ¿î²úÆ·Affymetrix CytoScan Dx Assay±»FDAÅú×¼£¬ÓÃÓÚÓëȾɫÌåÒì³£Ïà¹ØµÄÏÈÌìÐÔ¼²²¡£¨Èç¶ùͯ·¢Óý³Ù»º»òÖÇÁ¦Õϰ­µÈ£©µÄ¼ì²â£¬ÓÃÓÚȾɫÌå½á¹ûÒì³££¨È±Ê§ÓëÖØ¸´£©µÄ¼ì²â¡£

ÅäºÏÈ«ÇòΨһµÄͨ¹ýÖйúCFDA/ÃÀ¹úFDA/Å·ÃËCE-IVDÈÏÖ¤µÄ»ùÒòоƬɨÃèϵͳGCS 3000Dx v.2£¬Affymetrix CytoScan HDºÍ750KоƬ±»¹ã·ºµÄÓÃÓÚ¶ùͯÒÅ´«²¡ÁÙ´²Õï¶Ï¡£

percentage of genes covered

(25 markers/100 kb)

CytoScan HD

CytoScan 750K

ISCA constitutional genes (340)

¹ú¼ÊÒÅ´«Ñ§Ð¾Æ¬±ê׼Э»á»ùÒò¿â

100%

100%

Cancer genes (526) °©Ö¢»ùÒò

100%

100%

OMIM Morbid genes (2,640) Ãϵ¶ûÒÅ´«²¡»ùÒò¿â

98%

83%

X chromosome OMIM Morbid genes (177) XȾɫÌå

100%

93%

RefSeq genes (36,121)

96%

80%

ϱíÊÇÉϺ£½»Í¨´óѧҽѧԺ¸½ÊôÉϺ£¶ùͯҽѧÖÐÐÄÀûÓÃCytoScan HDµÈ»ùÒòоƬ¿ªÕ¹µÄ500Àý¶ùͯ²»Ã÷Ô­ÒòÖÇÁ¦ÂäºóµÄ¼ì²â½á¹û¡£

4¡¢¿Í»§·¢±íµÄÎÄÕ¾ÙÀý

1. Discovery of a previously unrecognized microdeletion syndrome of 16p11.2¨Cp12.2

ͨѶ×÷ÕߣºLisa G Shaffer£¨»ªÊ¢¶ÙÖÝÁ¢´óѧ£©
·¢±íÔÓÖ¾£ºNature Genetics, 2007, 39: 1071-1073 Ó°ÏìÒò×Ó£º31.616
ÄÚÈݼò½é£ºÍ¨¹ý»ùÒòоƬµÈ¼¼ÊõÔÚ4¸ö·¢ÓýÕϰ­µÄ»¼ÕßÉíÉÏ·¢ÏÖÒ»¸öеÄÔÚ×ÅË¿Á£ÇøÓòµÄ΢ȱʧ×ÛºÏÕ÷

2. Genetic variants regulating ORMDL3 expression contribute to the risk of childhood asthma

ͨѶ×÷ÕߣºWilliam O. C. Cookson£¨Ó¢¹úµÛ¹úÀí¹¤Ñ§Ôº£©
·¢±íÔÓÖ¾£ºNature. 2007, 448: 470-473 Ó°ÏìÒò×Ó£º38.138
ÄÚÈݼò½é£ºÍ¨¹ý»ùÒòоƬµÈ¼¼ÊõÑо¿»ùÒòÍ»±ä¶ÔÓë¶ùÍ¯Ïø´­Ïà¹Ø»ùÒò±í´ïµÄÓ°Ïì

3. Smaller and larger deletions of the Williams Beuren syndrome region implicate genes involved in mild facial phenotype, epilepsy and autistic traits

ͨѶ×÷ÕߣºGiuseppe Merla£¨IRCCS Casa Sollievo Della Sofferenza Ò½Ôº£¬Òâ´óÀû£©
·¢±íÔÓÖ¾£ºEuropean Journal of Human Genetics, 2014, 2: 64¨C70 Ó°ÏìÒò×Ó£º4.58
ÄÚÈݼò½é£ºÍ¨¹ý»ùÒòоƬµÈ¼¼Êõ¼ø¶¨Williams Beuren×ÛºÏÕ÷ÇøÓòµÄ´óСȱʧ£¬¿É·¢ÏÖÓëÇá¶ÈÃæ²¿±íÐ͵Äñ²ðïºÍ×Ô±ÕÖ¢ÌØÕ÷Ïà¹ØµÄ»ùÒò

5¡¢¹úÄÚ¶ùͯҽԺ/¶ù¿ÆÏà¹ØAffymetrix»ùÒòоƬ¿Í»§

ÉϺ£¶ùͯҽѧÖÐÐÄ£¬ÉϺ£ÊÐлªÒ½Ôº£¬ÖйúÈËÃñ½â·Å¾ü×ÜÒ½Ôº£¬¹ú¼Ò¼ÆÉúί¿ÆÑÐËù£¬²©°Â¹«Ë¾£¬É½Î÷¼ÆÉúί£¬Î÷¾©Ò½Ôº£¬Ö£ÖÝ´óѧµÚÈý¸½ÊôÒ½Ôº£¬³É¶¼Êи¾Ó×±£½¡Ôº£¬»ªÎ÷Ò½Ôº£¬ÖØÇì¶ùͯҽԺ£¬¹ãÖÝÊи¾Å®¶ùͯҽÁÆÖÐÐÄ£¬ÖÐɽҽ¿Æ´óѧµÚÒ»¸½ÊôÒ½Ôº£¬ÖÐɽ´óѧ¸½ÊôµÚ¶þÒ½Ôº£¬½ðÓòҽѧ¼ìÑéÖÐÐÄ£¬ÉîÛڼƻ®ÉúÓýÑо¿Ôº£¬ÄϾ©¹ÄÂ¥Ò½Ôº£¬Õã½­Ê¡¸¾Ó×±£½¡Ôº£¬¼ÎÐËÊи¾Ó×£¬ÉϺ£ÊеÚÒ»¸¾Ó¤±£½¡Ôº£¬¼ÃÄÏÊи¾Ó×±£½¡Ôº£¬ÇൺÊи¾Å®¶ùͯҽԺ£¬Î人¿µÊ¥´ïҽѧ¼ìÑéËùµÈ¡£

Á˽âApplied Biosystems ²âÐòƽ̨¸ü¶àÓ¦ÓÃÐÅÏ¢£¬ÇëÁ¢¿ÌË÷È¡Applied Biosystems ²âÐòм¼Êõ×ÊÁÏ£¡


Èý¡¢Ã«Ï¸¹ÜµçÓ¾»ùÒò·ÖÎö¼¼ÊõÔÚ¶ùͯÏà¹Ø·Ö×Ó¼ì²âÖеÄÓ¦ÓÃ

1¡¢¼¼Êõ¶¨Î»

ëϸ¹ÜµçÓ¾»ùÒò·ÖÎöƽ̨ÊʺÏÓÃÓÚµ¥»ùÒò»òÉÙÁ¿ÒÑ֪λµã£¨<30£©Ïà¹ØµÄ¼²²¡µÄ·Ö×ÓÕï¶Ï£¬Èçµ¥»ùÒòÒÅ´«²¡£¬ÒÔ¼°Ç××Ó¼ø¶¨¡£

2¡¢ÍƼö²úÆ·¡ª¡ªApplied Biosystems 3500Dx»ò3500xL Dx»ùÒò·ÖÎöÒÇ

Applied BiosystemsµÄëϸ¹ÜµçӾƽ̨¡ª¡ª»ùÒò·ÖÎöÒÇÊÇëϸ¹ÜµçÓ¾»ùÒò·ÖÎöµÄÐÐÒµ±ê×¼£¬ÊÇÒµÄÚ×î¿É¿¿¡¢¸ßЧºÍ·¢±íÎÄÏ××î¶àµÄDNAÐòÁзÖÎö¼¼Êõ¡£Applied Biosystems 3500DxºÍ3500xL Dx»ùÒò·ÖÎöÒÇÊǾ­¹ýCFDAÈÏÖ¤µÄ×îвúÆ·£¬·Ö±ðÖ§³Ö8µÀ£¨¿ÉÉý¼¶24µÀ£©ºÍ24µÀ¼ì²âͨÁ¿¡£

3¡¢¿É¿ªÕ¹µÄÁÙ´²ÏîÄ¿»òÑо¿¡ª¡ªµ¥»ùÒòÒÅ´«²¡¡¢Ç××Ó¼ø¶¨µÈ·Ö×Ó¼ì²â

3500»ùÒò·ÖÎöƽ̨Äܹ»ÔËÐжàÖÖÀàÐ͵ÄÓ¦Ó㬰üÀ¨Ð»ùÒò²âÐòºÍÖØ²âÐò£¨Í»±äͼÆ×£©£¬ÒÔ¼°Î¢ÎÀÐÇ·ÖÎö¡¢MLpA¡¢LOH¡¢ApLp¡¢MLSTºÍSNpµÄÑéÖ¤ºÍɸѡ¡£Óë¶ùͯÏà¹ØµÄÓ¦ÓÃÏîÄ¿Ö÷ÒªÊǵ¥»ùÒòÒÅ´«²¡ºÍÇ××Ó¼ø¶¨¡£

µ¥»ùÒòÒÅ´«²¡Ä¿Ç°ÒÑ·¢ÏÖ7000ÓàÖÖ£¬Ä³Ð©µ¥»ùÒò²¡ÊDz»¿ÉÖÎÓú²¢ÑÏÖØÓ°Ï컼¶ùÉú»îÖÊÁ¿µÄ³öÉúȱÏÝ£¬²»½öÓ°Ïìµ½¶ùͯÉúÃü½¡¿µÓëÉú»îÖÊÁ¿£¬½µµÍ³öÉúÈ˿ڵÄËØÖÊ£¬¸üÊÇÉîÉîÓ°Ïìµ½¼ÒÍ¥µÄÐÒ¸£ºÍг¡£µ¥»ùÒòÒÅ´«²¡ÊÊÓÃÓÚÒòµ¥¸ö»ùÒòÒì³£¶øµ¼ÖµÄÒÔÃϵ¶û·½Ê½ÒÅ´«µÄ¼²²¡£¬°üÀ¨³£È¾É«ÌåÏÔÐÔ¡¢ÒþÐÔÒÅ´«£¬ÐÔȾɫÌåÏÔÐÔ¡¢ÒþÐÔÒÅ´«²¡¡£ÀíÂÛÉÏÖ»ÒªÓÐ×ã¹»µÄÐòÁÐÐÅÏ¢£¬ÓÐÃ÷È·µÄ»ùÒòÕï¶Ï£¬»ùÒòÕï¶ÏÄÜÕë¶ÔÈκÎÒÅ´«²¡½øÐС£

¾ÙÀý1¡¢±½±ûͪÄòÖ¢»ùÒò¼ì²â

¼²²¡¸ÅÊö

▪98%µÄ»¼¶ùÒò±½±û°±ËáôÈ»¯Ã¸»ùÒòpAHÍ»±ä£¬ÎÞ·¨½«±½±û°±Ëáת»¯ÎªÀÒ°±Ëá
▪pAH»ùÒòλÓÚ12ºÅȾɫÌåq24.1ÇøÓò£¬1.5Mb£¬°üº¬13¸öÍâÏÔ×Ó
▪ÒѾ­·¢ÏÖ440¶àÖÖpAHÖ²¡ÐÔÍ»±ä£¬¹úÄÚ30ÓàÖÖ
▪Í»±äδ֪¶à±ä£¬Éæ¼°ÇøÓò¹ã·º£»Í»±äÀàÐͶàÑù

ÁÙ´²ÒâÒå

▪±½±ûͪÄòÖ¢ÊÇÉÙÊý¿ÉÒÔÖÎÁƵÄÒÅ´«²¡Ö®Ò»£¬ÔçÆÚÕï¶ÏÊǾö¶¨±½±ûͪÄòÖ¢Ô¤ºóµÄ¹Ø¼ü
▪³öÉúºó1¸öÔÂÄÚ½ÓÊÜÖÎÁÆÕß¶àÊý¿ÉÄܲ»³öÏÖÖÇÁ¦Ë𺦣¬ÖÎÁÆÔ½Íí£¬¶ÔÄÔµÄËðÉËÔ½Ã÷ÏÔ¡£Òò´Ë£¬»¼¶ùÒ»µ©È·ÕӦÁ¢¼´¸øÓèÖÎÁÆ£¬ÖÎÁÆÔ½Ô磬ԤºóÔ½ºÃ¡£
▪¶Ô±½±û°±ËáôÈ»¯Ã¸£¨pAH£©»ùÒò3,6,7,11,12ÍâÏÔ×Ó½øÐвâÐò¼ø¶¨Í»±äÊÇÕï¶ÏµÄ×î¼Ñ·½°¸£¨ÏÂͼΪ²âÐò½á¹û·ÖÎöʾÒâͼ£©

¾ÙÀý2¡¢»ùÓÚÒ»´ú²âÐòMLpA¼¼ÊõµÄ¶ÅÊϼ¡ÓªÑø²»Á¼£¨DMD£©µÄ»ùÒò¼ì²â

MLpA¼¼Êõ

¶àÖØÁ¬½ÓÒÀÀµÌ½ÕëÀ©Ôö£¨Multiplex Ligation-dependent probe Amplification£¬MLpA£©²ÉÓöàÖØpCRµÄ·½Ê½½øÐкËËáÑùÆ·¼ì²â£¬Äܹ»ÔÚÒ»¸ö¼òµ¥µÄ·´Ó¦ÄÚ¼ì²â¶à´ï50¸öÌØÒìºËËáÐòÁеĿ½±´Êý±ä»¯ £¬Òò´ËÄܹ»¼ì²â´óÁ¿»ùÒòµÄȱʧºÍÖØ¸´Í»±ä¡£MLpAÒѱ»¹«ÈÏΪһÖÖ¿É¿¿ÓÐЧµÄ·½·¨£¬×Ô2002ÄêÊ״ᨵÀÒÔÀ´£¬ÒÑÔÚÈ«Çò900¶à¼ÒʵÑéÊÒʹÓ㬹㷺ӦÓÃÓÚ¿½±´Êý±äÒìËùÖ¼²²¡µÄ»ùÒòÕï¶Ï¡£

¼²²¡¸ÅÊö

¶ÅÊϼ¡ÓªÑø²»Á¼£¨DMD£©ºÍ±´Êϼ¡ÓªÑø²»Á¼£¨BMD£©ÊÇÓɱàÂë¼¡ÓªÑø²»Á¼µ°°×£¨dystrophin£©µÄDMD»ùÒòÍ»±äÒýÆð¡£¸Ã»ùÒòÊÇĿǰ·¢ÏÖµÄÈËÀà×î´óµÄ»ùÒò£¬³¤2.4Mb£¬º¬80¸öÍâÏÔ×Ó£¬ÆäÖ÷Ҫͻ±äÀàÐÍΪÍâÏÔ×Óȱʧ£¬Õ¼È«²¿Í»±äµÄ50~70%£¬µãÍ»±äÔ¼Õ¼25%£¬Öظ´Í»±äÔ¼Õ¼5~10%£¬Í»±äλÖÃÎ޹̶¨¹æÂÉ¡£ÓÉÓÚDMD»ùÒò½á¹¹¸´ÔÓ£¬Í»±äÐÎʽ¶àÑù£¬ÁÙ´²¼ì²âÄѶȺܴó¡£MLpA p034/p035ÊÔ¼ÁºÐÓÃÓÚ¼ì²âDNAÑùÆ·ÖÐDMD»ùÒòÒ»¸ö»òÊý¸öÍâÏÔ×ÓµÄȱʧ»òÖØ¸´¡£ÔÚÄÐÐÔ»¼ÕßÑùÆ·ÖУ¬XȾɫÌåÉÏijһÍâÏÔ×ÓµÄȱʧ»áµ¼ÖÂÏàӦ̽ÕëÐźÅÍêÈ«Ïûʧ£¬µ«ÔÚÅ®ÐÔЯ´øÕßÑùÆ·ÖÐÖ»»á²úÉú35~50%µÄ·åÃæ»ý½µµÍ¡£

Ç××Ó¼ø¶¨¾ÍÊÇÔËÓÃÏÖ´úҽѧºÍÉúÎïѧ¼¼Êõ£¬¼ì²â¶Ô±È¸¸Ä¸Óë×ÓÅ®¼äµÄÒÅ´«±ê¼Ç½øÐÐÇ×Éú¹ØÏµµÄ¼ø¶¨¡£ThermoFisherµÄÒ»´ú²âÐò/»ùÒò·ÖÎöÒÇÊÇÈ«ÇòµÚÒ»Æ·ÅÆ£¬¹ã·ºÓÃÓÚÇ××Ó¼ø¶¨¼ì²â¡£ThermoFisherÄܹ»ÌṩÇ××Ó¼ø¶¨ËùÐèµÄÈ«Ì×ÊÔ¼Á¡¢ÒÇÆ÷ºÍÈí¼þ¡£ÐÂÒ»´ú·¨Ò½¼ø¶¨¼°Ç××Ó¼ø¶¨ÊÔ¼ÁºÐAmpFlSTR Identifiler pCRÀ©ÔöÊÔ¼ÁºÐÊÇÒ»¸ö¶àÖØ¶Ì´®ÁªÖظ´ÐòÁУ¨STR£©¼ì²âÊÔ¼ÁºÐ¡£Ëü²ÉÓÃ×îеÄÎåɫӫ¹â¡¢Ò»¸öÓ¾µÀ¼¼Êõ£¬¿ÉÒÔͬʱÀ©ÔöºÍͬʱ¼ì²â16¸öSTRλµã£¨15¸ö4ºËÜÕËáÖØ¸´Î»µã¼ÓÉÏAmelogeninÐÔ±ðÅж¨±ê¼Ç£©¡£¿ÉÒÔÓÃÓÚ¸öÈËÇ××Ó¼ø¶¨£¬Ë¾·¨Ç××Ó¼ø¶¨£¬¹¬ÄÚÇ××Ó¼ø¶¨£¬Ç×Ôµ¼ø¶¨£¬¸öÌåʶ±ðµÈ¡£

4¡¢¿Í»§¿ªÕ¹µÄÏîÄ¿¾ÙÀý

£¨1£©Î人ͬ¼ÃÒ½Ôº

£¨2£©ÖÐÐÅÏæÑÅÉúÖ³ÓëÒÅ´«×¨¿ÆÒ½Ôº

£¨3£©¹ãÖÝÒ½¿Æ´óѧ¸½ÊôµÚÈýÒ½Ôº

5¡¢¹úÄÚ¿Í»§·¢±íµÄÎÄÕ¾ÙÀý

1. Clinical phenotypes and Genotypic Spectrum of Cystic Fibrosis in Chinese Children

ͨѶ×÷ÕߣºÕÔ˳Ӣ£¨±±¾©¶ùͯҽԺ£©
·¢±íÔÓÖ¾£ºJournal of pediatrics. 2016, 171:269-276 Ó°ÏìÒò×Ó£º3.89
ÄÚÈݽéÉÜ£º±³¾°£ºÄÒÐÔÏËά»¯(CF)ÊǸ߼ÓË÷ÈËȺÖÐ×î³£¼ûµÄÒÅ´«ÐÔ¼²²¡£¬´Ë²¡Òѱ»Ö¤ÊµÓëCFTRµÄ»ùÒòÍ»±äÓйØ¡£È»¶ø£¬ÄÒÐÔÏËά»¯ÔÚÖйúÈËȺÖÐÏ൱º±¼û£¬ÖÁ½ñ½öÓм«ÉÙÁ¿µÄCF²¡Àý±»±¨µÀ¡£·½·¨£º·ÖÎö21ÀýÈ·ÕïÄÒÐÔÏËά»¯µÄÖйú¶ùͯµÄÁÙ´²±íÐͼ°»ùÒòÐÍ¡£½á¹û£º(1)Ö§Æø¹ÜÀ©ÕÅ(95.2%)ÒÔ¼°±Çñ¼Ñ×(76.2%)Ϊ×îÖ÷ÒªµÄÁÙ´²ÌØÕ÷£¬¶øÒÈÏÙÍâ·ÖÃÚ¹¦Äܲ»È«È´ºÜº±¼û(14.3%)¡£ÆøµÀ×îÖ÷ÒªµÄÖ²¡²¡Ô­ÎªÍ­Â̼ٵ¥°û¾ú(66.7%)¡£CFµÄ¶ùͯ´æÔÚÏÔÖøµÄ·Î¹¦ÄܵÍÏÂFEV1 (71.8¡À17.2%Ô¤¼ÆÖµ)£¬FEF75 (33.7¡À20.4%Ô¤¼ÆÖµ)¡£(2)ͨ¹ý»ùÒò²âÐò±È¶Ô£¬ÎÒÃÇ·¢ÏÖÁË22ÖÖ²»Í¬µÄCFTR»ùÒòÍ»±ä£¬°üÀ¨12ÖÖ´íÒåÍ»±ä£¬5ÖÖÎÞÒåÍ»±ä£¬2ÖÖ¿òÒÆÍ»±ä£¬1ÖÖ·ÇÒÆÂë²åÈ룬1ÖÖ¼ôÇÐλµãÍ»±ä£¬1ÖÖ3"UTRÇøÍ»±ä¡£ÆäÖУ¬ÓÐ7ÖÖÍ»±äΪз¢Í»±ä(W216X[780G¡úA], 1092insA, Q359X, D567Y, 2623-126T¡úC, 3439delA , 4575+110C¡úG)¡£Öйú¶ùͯÖÐ×î³£¼ûµÄÍ»±äÀàÐÍΪL88XºÍI556V£¬ËùÓеÄÍ»±äÀàÐ;ù·Ç¸ß¼ÓË÷ÈËCFTRµÄ³£¼ûÍ»±ä¡£½áÂÛ£ºÄÒÐÔÏËά»¯ÔÚÖйú¶ùͯÖÐÆÕ±é´æÔÚ©ÕïÏÖÏ󣬿ÉÄܹéÒòÓÚ¶Ô¼²²¡µÄÈÏʶ²»×ãÒÔ¼°Õï¶Ï·½·¨µÄ¾ÖÏÞ¡£Öйú¶ùͯÄÒÐÔÏËά»¯µÄ±íÐͺͻùÒòÐÍÓë¸ß¼ÓË÷ÈËÏà±È´æÔںܴóµÄ²îÒì¡£

2. Evolutionary History and Ongoing Transmission of phylogenetic Sublineages of Mycobacterium tuberculosis Beijing Genotype in China

ͨѶ×÷ÕߣºÉê°¢¶«£¬Íò¿µÁÖ£¬Igor Mokrousov£¨±±¾©¶ùͯҽԺ£¬Öйú¼²¿ØÖÐÐÄ£¬Ê¥±ËµÃ±¤°Í˹µÂÑо¿Ëù£©
·¢±íÔÓÖ¾£ºScientific Reports. 2016, 6:34353 Ó°ÏìÒò×Ó£º5.228
ÄÚÈݽéÉÜ£º±±¾©»ùÒòÐͽáºË·ÖÖ¦¸Ë¾úÆðÔ´ÓÚÖйú£¬²¢ÔÚÉϸöÊÀ¼Í¹ã·º´«²¥ÓÚÈ«Çò¡£±¾ÎÄͨ¹ý²ÉÓÃ24-λµãMIRU-VNTR·ÖÐÍ·¨ºÍÏÖ´úÖê-¹Å´úÖê·ÖÐÍ·¨½«À´×ÔÖйú¶à¸öÊ¡Êеı±¾©»ùÒòÐͽáºË·ÖÖ¦¸Ë¾ú¾úÖê½øÐлùÒò·ÖÐÍ£¬×ܽ᲻ͬ»ùÒòÐ;úÖêµÄ·Ö×ÓÌØÕ÷¡¢µØÓò²îÒì¼°ËÞÖ÷ÌØÕ÷£¬µÃ³ö£º¿Õ¼ä¾àÀëÈÔÊǽáºË·ÖÖ¦¸Ë¾úȺÌå»ùÒòÒìÖÊÐԵľö¶¨ÐÔÒòËØÖ®Ò»£¬²»Í¬µØÓòÀ´Ô´¾úÖêµÄ¶àÑùÐÔºÍÍøÂçÍØÆË½á¹¹·ÖÎöÊý¾ÝËÆºõҲ֤ʵÁ˱±¾©¼Ò×å¾úÖêÀ´Ô´ÓÚÖйúÄÏ·½µØÇø;ͬʱ£¬½«±¾ÎĽá¹ûÓëÅ·ÑDZ³¾°½áºÏ·ÖÎö·¢ÏÖ¶íÂÞ˹B0/W148¾úÖêºÍÑÇ/¶íA0/94-32ÖØÒªÁ÷ÐпË¡Öê¿ÉÄÜ·Ö±ðÆðÔ´ÓÚÖйú¶«±±²¿ºÍÎ÷±±²¿;¶ùͯËÞÖ÷À´Ô´µÄÏÖ´úÖê³É´ØÂʽϸߣ¬µ«¶ùͯÄͶàÒ©½áºË¾úÖêÔÚ¸÷ÑÇϵ¾úÖêÖоùÎÞÏÔÖøÔö¸ß£¬ÕâÌáʾ¾úÖê³É´Ø¿ÉÄÜÓëÄÍÒ©Î޹أ¬¶øÓëÆäËûÄܹ»Ìá¸ßÎÒ¹úÏÖ´ú¾úÖê´«²¥ÄÜÁ¦µÄÌØÐÔÏà¹Ø£¬Èç¾úÖê¶¾Á¦ÒòËØµÈ¡£

3. Compensatory Mutations of Rifampin Resistance Are Associated with Transmission of Multidrug-Resistant Mycobacterium tuberculosis Beijing Genotype Strains in China

ͨѶ×÷ÕߣºÉê°¢¶«£¨±±¾©¶ùͯҽԺ£©
·¢±íÔÓÖ¾£ºAntimicrob Agents Chemother. 2016, 60: 2806-2812 Ó°ÏìÒò×Ó£º4.415
ÄÚÈݽéÉÜ£ºÄÍÒ©½áºË²¡£¬ÓÈÆäÊÇÄͶàÒ©½áºË²¡(MDR-TB)µÄ³öÏÖ¸ø½áºË²¡µÄ·À¿Ø´øÀ´ÁËÑϾþµÄÌôÕ½¡£Àû¸£Æ½(RIF)ÊÇ¿¹½áºËÖÎÁÆÖÐÖØÒªµÄÒ»ÏßÒ©Î90%ÒÔÉϵÄRIFÄÍÒ©Öê´æÔÚrpoBÍ»±ä¡£Ñо¿±íÃ÷£¬rpoBÍ»±äºóͨ³£°éËæÓÐϸ¾úµÄÊÊÓ¦ÐÔϽµ£¬¶ørpoAºÍrpoC»ùÒò(·Ö±ð±àÂëRNA¾ÛºÏø¦ÁºÍ¦Â¡¯ÑÇ»ù)ÉϵÄÍ»±ä¿ÉÒÔ¸ÄÉÆÕâÖÖÊÊÓ¦ÐÔ´ú¼Û¡£Ä¿Ç°ÎÒ¹úRIFÄÍÒ©¾úÖêÖÐrpoAºÍrpoC»ùÒòÍ»±äµÄÇé¿ö¼°ÆäÔÚ¾úÖê´«²¥¹ý³ÌÖеÄ×÷Óò¢²»Ã÷È·¡£±¾Ñо¿ÊÕ¼¯ÁË2011-2013ÄêÆÚ¼äÔÚ±±¾©ÐØ¿ÆÒ½Ôº¾ÍÕïµÄ½áºË²¡È˵ÄÁÙ´²·ÖÀëÖê510Ö꣬°üÀ¨RIFÄÍÒ©¾úÖê331ÖêºÍRIFÃô¸Ð¾úÖê179Öê¡£¶ÔËùÓÐÈë×é¾úÖê½øÐÐVNTR-MIRU(24λµã)»ùÒò·ÖÐÍ£¬ÒÔ¼°rpoBÄÍÒ©ºËÐÄÇø(RRDR)¡¢rpoAºÍrpoC»ùÒòµÄÐòÁвⶨ¡£ÒÔÁ˽âÎÒ¹ú±±·½µØÇø½áºË·ÖÖ§¸Ë¾ú(MTB)ÖÐrpoAºÍrpoC»ùÒòÍ»±äµÄÇé¿ö¼°ÆäÔÚ¾úÖê´«²¥ÖеÄ×÷Óá£
½áÂÛ£ºrpoAºÍrpoC»ùÒòÍ»±äÔÚÎÒ¹úMTB¾úÖêÖнÏΪÁ÷ÐУ¬ÒÔrpoCÍ»±äΪÖ÷£¬ÇÒ¿ÉÄÜÓëRIFÄÍÒ©ÐԵIJúÉúÏà¹Ø;Я´ørpoC»ùÒòÍ»±äµÄMDR¾úÖê´«²¥ÄÜÁ¦¸üÇ¿¡£

ËÄ¡¢Ó«¹â¶¨Á¿pCR¼¼ÊõÔÚ¶ùͯ¼²²¡Ïà¹Ø·Ö×Ó¼ì²âÖеÄÓ¦ÓÃ

1¡¢¼¼Êõ¶¨Î»

Ó«¹â¶¨Á¿pCRÊʺÏÓÃÓÚµ¥»ùÒò»òÉÙÁ¿ÒÑ֪λµã£¨<20£©Ïà¹ØµÄ·Ö×ÓÕï¶Ï£¬È紫Ⱦ²¡¡¢µ¥»ùÒòÒÅ´«²¡ºÍÒ©Îï»ùÒò×飨pGx£©µÄ·Ö×Ó¼ì²â¡£

2¡¢ÍƼö²úÆ·¡ª¡ªApplied Biosystems 7500DxÓ«¹â¶¨Á¿pCRϵͳ

Applied Biosystems 7500DxÊÇÈ«ÇòÏúÁ¿×î´ó¡¢Ö§³ÖÁÙ´²·Ö×ÓÕï¶ÏÊÔ¼ÁºÐ×î¶àµÄÓ«¹â¶¨Á¿pCRϵͳ¡£¸ÃϵͳÊÇÒ»¸ö¹¦ÄÜÇ¿´óµÄƽ̨£¬Äܹ»Ö§³Ö¶à´ï5¸öͨµÀµÄÓ«¹âͬʱ¼ì²â¡£

3¡¢¿É¿ªÕ¹µÄÁÙ´²ÏîÄ¿»òÑо¿¡ª¡ª´«È¾²¡¡¢µ¥»ùÒòÒÅ´«²¡¡¢Ò©Îï»ùÒò×éµÈ·Ö×Ó¼ì²â

ÒÔÏÂÁгöÀ´½ØÖÁ2016Äê11ÔÂ29ÈÕ£¬ÔÚÓ«¹â¶¨Á¿pCRƽ̨ÉÏ¿ÉÒÔ¿ªÕ¹µÄ´«È¾²¡¡¢µ¥»ùÒòÒÅ´«²¡¡¢Ò©Îï»ùÒò×éÏà¹ØµÄ²¿·Ö·Ö×ÓÕï¶ÏÊÔ¼ÁºÐ£¨CFDAÅú×¼£©¡£ÆäÖУ¬·Ç³£¶àµÄÊÔ¼ÁºÐÒ²¿ÉÒÔÓÃÓÚ¶ùͯÏà¹Ø´«È¾²¡¡¢ÒÅ´«²¡ºÍÒ©Îï´úлÏà¹ØµÄ·Ö×ÓÕï¶Ï¡£